Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?

Rosario Sanguedolce, Anna Calascibetta, Carlo Pavone, Rossana Porcasi, Michele Pavone-Macaluso, Rosa Maria Tomasino, Anna Calascibetta, Rossana Porcasi, Rosario Sanguedolce, Darwin Melloni, Carlo Pavone

Risultato della ricerca: Article

2 Citazioni (Scopus)

Abstract

Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay. Results: GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7% of patients. Seven patients (11.6%) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors. Conclusion: At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.
Lingua originaleEnglish
pagine (da-a)2971-2976
Numero di pagine6
RivistaAnticancer Research
Volume22
Stato di pubblicazionePublished - 2002

Fingerprint

Transitional Cell Carcinoma
P-Glycoprotein
Urinary Bladder
Recurrence
Urinary Bladder Neoplasms
Drug Therapy
Immunohistochemistry
Neoplasms
Pharmaceutical Preparations
Monoclonal Antibodies
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cita questo

Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder? / Sanguedolce, Rosario; Calascibetta, Anna; Pavone, Carlo; Porcasi, Rossana; Pavone-Macaluso, Michele; Maria Tomasino, Rosa; Calascibetta, Anna; Porcasi, Rossana; Sanguedolce, Rosario; Melloni, Darwin; Pavone, Carlo.

In: Anticancer Research, Vol. 22, 2002, pag. 2971-2976.

Risultato della ricerca: Article

Sanguedolce, R, Calascibetta, A, Pavone, C, Porcasi, R, Pavone-Macaluso, M, Maria Tomasino, R, Calascibetta, A, Porcasi, R, Sanguedolce, R, Melloni, D & Pavone, C 2002, 'Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?', Anticancer Research, vol. 22, pagg. 2971-2976.
Sanguedolce, Rosario ; Calascibetta, Anna ; Pavone, Carlo ; Porcasi, Rossana ; Pavone-Macaluso, Michele ; Maria Tomasino, Rosa ; Calascibetta, Anna ; Porcasi, Rossana ; Sanguedolce, Rosario ; Melloni, Darwin ; Pavone, Carlo. / Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?. In: Anticancer Research. 2002 ; Vol. 22. pagg. 2971-2976.
@article{3fa2ebdbfeaa4343934f3c45d5ecafe0,
title = "Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?",
abstract = "Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay. Results: GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7{\%} of patients. Seven patients (11.6{\%}) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors. Conclusion: At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.",
author = "Rosario Sanguedolce and Anna Calascibetta and Carlo Pavone and Rossana Porcasi and Michele Pavone-Macaluso and {Maria Tomasino}, Rosa and Anna Calascibetta and Rossana Porcasi and Rosario Sanguedolce and Darwin Melloni and Carlo Pavone",
year = "2002",
language = "English",
volume = "22",
pages = "2971--2976",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",

}

TY - JOUR

T1 - Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?

AU - Sanguedolce, Rosario

AU - Calascibetta, Anna

AU - Pavone, Carlo

AU - Porcasi, Rossana

AU - Pavone-Macaluso, Michele

AU - Maria Tomasino, Rosa

AU - Calascibetta, Anna

AU - Porcasi, Rossana

AU - Sanguedolce, Rosario

AU - Melloni, Darwin

AU - Pavone, Carlo

PY - 2002

Y1 - 2002

N2 - Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay. Results: GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7% of patients. Seven patients (11.6%) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors. Conclusion: At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.

AB - Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one cause of resistance to most drugs used in intravesical chemotherapy of superficial bladder cancer. Materials and Methods: GP-170 was retrospectively assessed in 60 patients affected by superficial transitional cell tumours of the bladder. It was assessed by immunohistochemistry in a semiquantitative way by the intensity of staining and by the percentage of positive cells. Correlation of GP-170 expression with G-grade, T-category, multiplicity, recurrence rate and treatment was investigated. In 44 patients recurrence was analysed in relation to GP-170 basal expression and to its variations. The monoclonal antibody JSB1 (DBA) at 1:20 dilution was employed for the GP-170 assay. Results: GP-170 expression increases with grade but was lower in multiple tumours. No difference between Ta and T1 categories was detected. GP-170 immunohistochemistry from different portions of the same tumour showed a very marked variability in 35.7% of patients. Seven patients (11.6%) were totally negative for GP-170. No statistically significant correlation was found between recurrence, progression and GP-170 basal expression. Similarly no correlation emerged between grade and stage variations at recurrence and modifications in GP-170 expression. One third of the tumours recurring after chemotherapy were negative for GP-170 in spite of an increase in recurrence rate and other risk factors. Conclusion: At the present stage of our experience, we have been unable to show that GP-170 is a useful marker for monitoring chemoresistance to intravesical chemotherapy in superficial bladder cancer. Furthermore, GP-170 determination has shown several technical difficulties.

UR - http://hdl.handle.net/10447/201354

M3 - Article

VL - 22

SP - 2971

EP - 2976

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

ER -